#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14624	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2072	699.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1409	1409	C	870	C	819	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26634	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3702	717.2	0	.	n	.	0	T695C	SNP	695	695	T	1190	1190	C	796	C,T	741,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26634	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3702	717.2	0	.	n	.	0	A1638G	SNP	1638	1638	A	2133	2133	G	846	G	798	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26634	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3702	717.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2466	2466	C	922	C,T	866,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26634	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3702	717.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2540	2540	A	898	A	838	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26634	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3702	717.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3092	3092	C	809	C,T	583,186	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2140	folP	855	855	100.0	folP.l15.c4.ctg.1	1522	139.9	1	SNP	p	R229S	1	.	.	685	687	AGC	1068	1070	AGC	211;212;214	A,G;G;C	200,1;202;203	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5972	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3293	180.6	1	SNP	p	S91F	1	.	.	271	273	TTC	531	533	TTC	208;209;205	T;T;C	198;199;195	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5972	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3293	180.6	1	SNP	p	G95N	0	.	.	283	285	GGC	543	545	GGC	201;202;200	G;G;C	191;187;185	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5972	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3293	180.6	1	SNP	p	D95G	1	.	.	283	285	GGC	543	545	GGC	201;202;200	G;G;C	191;187;185	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1646	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1398	117.4	1	SNP	p	G45D	0	.	.	133	135	GGC	474	476	GGC	215;217;218	G;G;C	202;204;202	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	830	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1140	72.6	0	.	n	.	0	A197.	DEL	197	197	A	700	700	A	201	A	188	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5490	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2866	190.7	1	SNP	p	D86N	0	.	.	256	258	GAC	508	510	GAC	220;218;216	G;A;C	206;203;207	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5490	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2866	190.7	1	SNP	p	R87W	0	.	.	259	261	CGT	511	513	CGT	218;222;220	C;G;T	211;212;209	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5490	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2866	190.7	1	SNP	p	S87R	1	.	.	259	261	CGT	511	513	CGT	218;222;220	C;G;T	211;212;209	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5490	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2866	190.7	1	SNP	p	R87I	0	.	.	259	261	CGT	511	513	CGT	218;222;220	C;G;T	211;212;209	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5490	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2866	190.7	1	SNP	p	S88P	0	.	.	262	264	TCC	514	516	TCC	219;221;222	T;C;C	209;212;213	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4390	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2518	173.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1493	1495	GGC	214;212;215	G;G;C	204;203;201	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	3864	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2435	158.0	1	SNP	p	A311V	0	.	.	931	933	GCC	1302	1304	GCC	207;207;207	G;C;C	195;195;195	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3864	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2435	158.0	1	SNP	p	I312M	1	.	.	934	936	ATG	1305	1307	ATG	209;212;211	A;T;G	199;201;201	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3864	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2435	158.0	1	SNP	p	T316P	0	.	.	946	948	ACC	1317	1319	ACC	209;212;212	A;C;C	196;198;200	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3864	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2435	158.0	1	SNP	p	V316T	1	.	.	946	948	ACC	1317	1319	ACC	209;212;212	A;C;C	196;198;200	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3864	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2435	158.0	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1818	1820	ACC	180;183;186	A;C;C	168;172;173	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3864	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2435	158.0	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1872	1874	GCG	185;192;193	G;C;G	174;181;182	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3864	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2435	158.0	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1872	1874	GCG	185;192;193	G;C;G	174;181;182	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3864	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2435	158.0	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1995	1997	GGT	176;175;176	G;G;T	162;162;159	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3864	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2435	158.0	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2004	2006	AGC	168;167;167	A;G;C	157;154;153	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3864	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2435	158.0	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2022	2024	CCG	131;130;129	C,G;C,G;G	101,10;102,1;104	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5616	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3083	181.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1631	1633	CCG	237;234;232	C;C,A;G	213;215,1;209	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2480	porA	1146	1146	99.91	porA.l6.c4.ctg.1	1879	131.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	608	608	C	180	C	166	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2778	porB1b	1038	1038	100.0	porB1b.l15.c4.ctg.1	1714	161.2	1	SNP	p	G120K	1	.	.	358	360	AAG	684	686	AAG	210;211;209	A;A;G	197;199;191	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2778	porB1b	1038	1038	100.0	porB1b.l15.c4.ctg.1	1714	161.2	1	SNP	p	N121D	0	.	.	361	363	AAC	687	689	AAC	209;210;210	A;A;C	196;198;201	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2778	porB1b	1038	1038	100.0	porB1b.l15.c4.ctg.1	1714	161.2	1	SNP	p	A121N	1	.	.	361	363	AAC	687	689	AAC	209;210;210	A;A;C	196;198;201	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10198	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4996	203.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1060	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1066	98.7	1	SNP	p	V57M	1	.	.	169	171	ATG	601	603	ATG	209;210;214	A;T;G,C	197;197;201,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
